CN103462989A - Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi - Google Patents
Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi Download PDFInfo
- Publication number
- CN103462989A CN103462989A CN 201310432483 CN201310432483A CN103462989A CN 103462989 A CN103462989 A CN 103462989A CN 201310432483 CN201310432483 CN 201310432483 CN 201310432483 A CN201310432483 A CN 201310432483A CN 103462989 A CN103462989 A CN 103462989A
- Authority
- CN
- China
- Prior art keywords
- lycojaponicumin
- human body
- preparation
- medicines
- body fungi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an application of Lycojaponicumin B in the preparation of medicines for resisting human body fungi, belonging to the field of medicines. The Lycojaponicumin B has very strong inhibitory effect on trichophyton rubrum, microsporum lanosum or trichophyton tonsurans. Therefore, the Lycojaponicumin B can serve as a compound capable of resisting human body fungi and is expected to be applied in the preparation of related medicines. The application of the Lycojaponicumin B in the preparation of the medicines for resisting human body fungi is disclosed for the first time. As the skeleton type of the Lycojaponicumin B belongs to a brand-new skeleton type, the Lycojaponicumin B has unexpected strong inhibitory activity on human body fungi, and the possibility that other compounds provide revelation does not exist. The Lycojaponicumin B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing and treating human body fungi infection.
Description
Technical field
The present invention relates to the purposes of Sarcaboside B, relate in particular to the application of Sarcaboside B in the anti-human body fungi-medicine of preparation.
Background technology
The mankind's health and lives in the enhancing serious threat of the diffusion of pathogenic bacterium and drug resistance thereof, antibacterials are widely used in acquired immune deficiency syndrome (AIDS) as routine administration, organ transplantation and Chronic consumptions are (as cancer, diabetes, uremia etc.) treatment, although the antimicrobial agent of using clinically at present is (as ketoconazole, amikacin, gentamycin, voriconazole, itraconazole, terbinafine, amphotericin, fluconazol etc.) better to the curative effect of skin and superficial place infection, but the cumulative toxicity of these antibacterials is stronger, usually cause lesions of liver and kidney, digestive tract stimulates, dizzy, irritated etc., become one of focus of current medicament research and development so find the novel antibacterial medicine of mechanism of action uniqueness.
The compound S arcaboside B the present invention relates to is one and within 2012, delivers (Li, X.et al., 2012.Two New-Skeleton Compounds from Sarcandra glabra.Helvetica Chimica Acta95 (6), 998-1002.) New skeleton compound, this compound has brand-new framework types, at present not about active report, purposes for the Sarcaboside B the present invention relates in the anti-human body fungi-medicine of preparation treatment belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for Human Fungi, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, the control of simultaneously infecting for Human Fungi obviously has significant progress.
Summary of the invention
The object of the invention is to:
The application of a kind of Sarcaboside B of the present invention in the anti-human body fungi-medicine of preparation is provided.
Described compound S arcaboside B structure is as shown in formula I:
Formula I
Sarcaboside B has the effect of very strong inhibition trichophyton, microsporum canis or trichophyton tonsurans, so Sarcaboside B can be used as the compound with the effect of anti-human body fungus, and is expected to be applied in the anti-human body fungi-medicine of preparation.
The purposes of the Sarcaboside B the present invention relates in the anti-human body fungi-medicine of preparation treatment belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for Human Fungi, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control of simultaneously infecting for Human Fungi obviously has significant progress.
The specific embodiment
The preparation method of compound S arcaboside B involved in the present invention is referring to document (Li, X.et al., 2012.Two New-Skeleton Compounds from Sarcandra glabra.Helvetica Chimica Acta95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound S arcaboside B tablet involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound S arcaboside B capsule involved in the present invention:
Get 20 and digest compound Sarcaboside B, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: the anti-human body fungi activity of Sarcaboside B
Anti-human body fungi activity experiment is the method that adopts concentration dilution, measures triplicate at every turn, and the test pathogen has trichophyton, microsporum canis and trichophyton tonsurans, and bacterial concentration is 10
5individual/mL.Sarcaboside B initial concentration is 50.0 μ g/mL(5% dimethyl sulfoxide DMSO), gradient dilution to 0.098 μ g/mL, the bacterium liquid of equivalent volumes and specimen Mixed culture are in 96 orifice plates, the Human Fungi cultivation temperature is respectively 28 ℃, after incubation time 24h, observe, while if find, not having bacterium colony to form, be the minimum anti-human body fungi concentration of sample, i.e. MIC value.This experiment positive control is ketoconazole, and the anti-human body fungus of Sarcaboside B the results are shown in Table 1.
Table 1Sarcaboside B anti-human body fungus MIC value (μ g/mL)
Conclusion: Sarcaboside B has very strong anti-human body fungi activity, and therefore Sarcaboside B of the present invention is expected to be used to prepare novel anti-human body fungi-medicine.
Claims (1)
1.Sarcaboside the application of B in anti-human body fungi-medicine, described compound S arcaboside B structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310432483 CN103462989A (en) | 2013-09-18 | 2013-09-18 | Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310432483 CN103462989A (en) | 2013-09-18 | 2013-09-18 | Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103462989A true CN103462989A (en) | 2013-12-25 |
Family
ID=49788187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310432483 Pending CN103462989A (en) | 2013-09-18 | 2013-09-18 | Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103462989A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188212A (en) * | 2014-06-25 | 2016-12-07 | 虞定生 | The application in antibacterials of Cleistanone derivant and pharmaceutically acceptable salt |
-
2013
- 2013-09-18 CN CN 201310432483 patent/CN103462989A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188212A (en) * | 2014-06-25 | 2016-12-07 | 虞定生 | The application in antibacterials of Cleistanone derivant and pharmaceutically acceptable salt |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462989A (en) | Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi | |
| CN103446115A (en) | Applications of Sarcaboside A in medicament against human fungus | |
| CN102872059B (en) | Application of Gypensapogenin B to preparing drugs for resisting human funguses | |
| CN102861087B (en) | Application of Houttuynoid D in anti-human fungi medicine | |
| CN103372004B (en) | Application of Chukrasone B in preparation of medicines for resisting human body fungi | |
| CN102861083B (en) | Application of Houttuynoid B in anti-human fungi medicine | |
| CN102872030B (en) | Application of Gypensapogenin B in antibacterial drugs | |
| CN103463029B (en) | Application of Lycojaponicumin B in human fungus resisting medicine | |
| CN102895238B (en) | Application of Gypensapogenin A in antibacterial medicament | |
| CN103479608A (en) | Application of Scopariusins in preparation of antihuman fungal medicines | |
| CN102872133B (en) | Application of Houttuynoid E in anti-human fungal drugs | |
| CN102872007A (en) | Application of Eryngiolide A in medicaments resisting human body fungi | |
| CN103446135B (en) | The application of Lycojaponicumin A in preparation anti-human fungi medicine | |
| CN103479636B (en) | The application of Lycojaponicumin C in preparation anti-human fungi medicine | |
| CN103462968B (en) | Incarviatone A is preparing the application in anti-bacterial drug | |
| CN102861027B (en) | Application of Gypensapogenin A in medicine for preventing human fungi | |
| CN103393696B (en) | Application of Chukrasone A for preparing antifungal drugs for human body | |
| CN102872145B (en) | Application of Houttuynoid C in anti-human fungal drugs | |
| CN103446095A (en) | Application of Incarviatone A in anti-human fungus drug | |
| CN103446114A (en) | Applications of Sarcaboside A in antibacterial medicament | |
| CN103393692B (en) | The application of compound in preparation anti-human fungi medicine | |
| CN105412063A (en) | Application of Kanshone C to preparing drug for resisting human body fungi | |
| CN103446125A (en) | Application of Lycojaponicumin B in antibacterial drug | |
| CN103463107A (en) | Application of Phyllanthoid A in preparing medicament for resisting human fungus | |
| CN105434425A (en) | Applications of Rhodomicranols A in preparing drugs used for inhibiting human body fungi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131225 |